Michael Fernando and Josh Hurwitz
Oncology for the Inquisitive Mind
Cancer is a fascinating but rapidly evolving discipline - it's a full-time job just keeping up to date. In this podcast, Dr Michael Fernando and Dr Joshua Hurwitz explore the latest trials, research, and practice-changing updates, as well as regular interviews with renowned oncology specialists. Ideal for those starting their training journey, established specialists and anyone interested in medical science, oncological practice, or terrible jokes. Preferably all three. Hosted on Acast. See acast.com/privacy for more information.
Be sure to visit the podcast's website and support the creator: www.inquisitiveonc.com
Author
Michael Fernando and Josh Hurwitz
Category
Podcast website
Latest episode
Nov 17, 2026
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
122. Palliative Care with Dr Janet Abrahm 27.07.2024 43:59
It is rare on any show to be able to interview a true pioneer. On today's episode of Oncology for the Inquisitive Mind, we have the privilege of interviewing Dr Janet Abrahm, a pioneer in every sense of the word. An internist with over 20 years experience, Dr Abrahm was one of the founders and earliest proponents of palliative care in the United States. A staff specialist at the Dana Farber Cancer...
121. Dr Elias Chandran, the NCI and Urothelial Caricinoma 20.07.2024 36:04
This week, we interview Dr Elias Chandran, a medical oncologist and emerging research juggernaut who is an assistant research physician at the National Cancer Institute in Bethesda, Maryland. His focus is on genitourinary cancer, and he has recently published a pivotal systematic review and meta-analysis titled " Mismatch repair deficiency and microsatellite instability-high in urothelial carcinom...
120. Artificial Intelligence & Cancer with Professor Meredith Broussard 13.07.2024 42:11
Today, Michael and Josh interview Professor Meredith Broussard to discuss Artificial Intelligence (AI), its role in cancer diagnosis, her journey with breast cancer and her inspiration for her latest book, More than a Glitch. Meredith is a data journalist at the Arthur L Carter Journalism Institute of New York University and has had an exceptionally versatile career, previously having worked as a...
119. ASCO 2024 - Plenary Session 17.06.2024 52:17
"Here at last, at the edge of the sea, comes the end of our Fellowship." So said Gandalf the White at the conclusion of J.R.R Tolkien's epic The Lord of the Rings . Today, Josh and Michael have a no less epic conclusion to their own adventure, that of ASCO 2024. Over the last fifteen days, our intrepid hosts have journeyed across the world of medical oncology, from the highs of colorectal, breast...
118. ASCO 2024 - Sarcoma 16.06.2024 19:51
Today is the penultimate episode in our ASCO 2024 Odyssey. Michael and Josh have neglected sarcoma to date, but today is the day@ Sarcoma is rare, where clinician experience becomes paramount to treatment options and outcomes. They develop in soft tissues and bones and vary in origin, including deep soft tissue, bone, nerves, etc. Today, they explore three trials. The first is paclitaxel and avelu...
117. ASCO 2024 - Central Nervous System 15.06.2024 25:27
Some consider the number 13 unlucky; fear of the number has its own name, "triskaidekaphobia." So it is perhaps somewhat fitting that day 13 of our ASCO Odyssey is dedicated to the cancer type with which scientists and doctors have had arguably the least luck in treating: central nervous system cancers. We still await CNS oncology's immunotherapy or EGFR/ALK moment, and unfortunately, as of ASCO 2...
116. ASCO 2024 - Early Lung Cancer & Mesothelioma 14.06.2024 28:06
ASCO 2024 beat many attendees' expectations with interesting and thought-provoking lung cancer and mesothelioma studies. While not all of these will change the face of patient treatment, they will add to a body of evidence for biomarkers and build on the blocks of tailoring treatment to patients. Links to studies discussed in this episode (subscription may be required): BEAT-meso: Link Checkmate 8...
115. ASCO 2024 - Head and Neck Cancer 13.06.2024 25:41
Our coverage of ASCO 2024 has rounded the final bend, and the finish line is in sight. Today, Josh and Michael examine four studies in the head and neck cancer space. Today's studies include a novel, viral-driven vector that aims to increase the immune response to treatment, potential treatment for the very rare nasal squamous cell cancer, data supporting the treatment of patients with poor progno...
114. ASCO 2024 - Early Colorectal Cancer 12.06.2024 23:50
ASCO 2024 never seems to end, and today, Michael and Josh do a bit of a backflip and report on the advancements in early colorectal cancer. Forever a confusing topic with PRODIGE23, OPRA, and many other rectal cancer trials and a spattering of neoadjuvant colorectal trials, the ability to redefine and provide clarity to this area is pertinent. Today, it heavily focuses on immunotherapy in the colo...
113. ASCO 2024 - Metastatic Colorectal Cancer 11.06.2024 22:48
Our 2024 ASCO epic trundles onto its next generation, advanced colorectal cancer. Over the last 10 years, treatment in this area has made incremental progress through the discovery of the clinically meaningful KRAS and BRAF mutation pathways and most recently with the potential for immunotherapy in the deficient mismatch repair (dMMR) and high microsatellite instability (MSI-H) subgroups. In this...
112. ASCO 2024 - Upper Gastrointestinal and Hepatobiliary Cancers 10.06.2024 29:05
Some oncologists may have already started counting down to ASCO 2025. However, Michael and Josh are still digesting the interesting world of ASCO 2024, specifically upper GI and Hepatobiliary Cancers. Like the eponymous lead of the 1992 classic Aladdin, several diamonds lie in the rough. We cover perioperative FLOT in the metastatic setting, but most excitingly, it is a potentially new groundbreak...
111. ASCO 2024 - Genitourinary Cancers (Prostate/Penile) 09.06.2024 26:33
The second of our two GU ASCO 2024 episodes focusses on prostate and penile cancer, two diseases at different ends of the therapeutic spectrum. Prostate cancer is one of the most common cancers in men, with well established, nuanced treatment paradigms and a glut of high-quality evidence. Penile SCC is a very rare cancer that tragically is much more common in low socioeconomic countries. Treatment...
110. ASCO 2024 - Genitourinary Cancers (Bladder/Kidney) 08.06.2024 26:44
Genitourinary Cancers dominated ASCO24 this year, and Josh and Michael's ASCO Odyssey needed two episodes to fit it all in. Join them as they board the Nautilus with Captain Nemo in search of the best trials to propel bladder and renal cancer to the forefront of your mind. This episode covers both the use of perioperative sacituzumab govitecan, avelumab as neoadjuvant therapy for bladder cancer an...
109. ASCO 2024 - Early Breast Cancer 07.06.2024 37:43
Unbeknownst to Josh, we are already at Day 5 of our ASCO Odyssey, and like Odysseus arriving at Circe's island of Aeaea, we have arrived at the episode devoted to early Breast Cancer. Today we examine four very interesting studies, looking at alternative immunotherapy strategies with adjuvant avelumab, adjuvant endocrine therapy omission in low-ER positive disease, ctDNA in predicting disease recu...
108. ASCO 2024 - Metastatic Breast Cancer 06.06.2024 34:57
Today, Michael and Josh approach a singular destiny to present their take on Metastatic Breast Cancer at ASCO 2024. Long has Breast Cancer been one of the most diagnosed cancers globally; these days, it leads the herd with effective treatment options and paradigm shifts that benefit millions of people on a massive scale. With CDK4/6 inhibitors, immunotherapy and antibody-drug conjugates, the arsen...
107. ASCO 2024 - Gynaecological Cancer 05.06.2024 33:47
Day 3 of Oncology for the Inquisitive Mind's ASCO Odyssey and our hosts show no sign of flagging under this immense pressure, although Josh has started to give up on his famous segues. In this episode, our intrepid hosts tackle gynaecological cancers, reporting on four of their favourite studies from a packed field of gynaecological cancers. Will new treatment options for cervical cancer emerge? W...
106. ASCO 2024 - Melanoma 04.06.2024 31:26
As the sun rises on another day at ASCO, Michael and Josh are ready to hit the ground running to bring you the latest and greatest in all things oncology in Chicago has to offer. No greek mythology today, only a burning desire to bring you the biggest melanoma trials from ASCO24. Today, they pack a punch, tackling some intriguing phase 1 trials with tongue-twisting names where the novelty wears of...
105. ASCO 2024 - Metastatic Non Small Cell Lung Cancer 03.06.2024 37:46
"Tell me, Muse, the story of that resourceful man who was driven to wander far and wide after he had sacked Troy. He saw the cities of many people and he learnt their ways. Tell us this story, goddess daughter of Zeus, beginning at whatever point you will." So begins Homer's epic The Odyssey , the story of the titular hero Odysseus' long, long, LONG journey from the ruins of Troy to his home of It...
104. Metastatic Gastric and GOJ Cancer 01.06.2024 25:54
With ASCO upon us, Michael and Josh squeeze one more episode of their regular schedule to bring you an important update on gastric cancer. For context, the 5 year survival rate for metastatic gastric cancer is 6%, similar to that of pancreatic cancer. Despite improvement in survival due to the addition of nivolumab to chemotherapy (Checkmate 64), few therapies have significantly changed it's overa...
103. Metastatic Colorectal Cancer 25.05.2024 30:38
Oncology research never sits still, nor does the desire for better treatment options for metastatic colorectal cancer. Fifty percent of diagnosed cases develop metastatic spread during their disease course. This week, we look for the "SUNLIGHT" and investigate the combination of Lonsurf with Bevacizumab and using Fruquintinib with refractory metastatic colorectal cancer. Links to articles discusse...
102. Hepatocellular Carcinoma 18.05.2024 33:24
Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer in the world and the third or fourth leading cause of death (depending on where you do your research). Over 70% of cases are in Asian countries, predominantly due to high rates of endemic hepatitis infections. This week, we climb a mountain in search of treatment options and advancements in this orphan cancer. Two trials are discuss...
Oncosnacks 14: Bevacizumab Toxicity (Part 1) 14.05.2024 15:43
In many parts of the world, Bevacizumab is an important component of the treatment of glioblastoma, colorectal, hepatocellular and ovarian cancers. However, with such widespread use inevitably comes toxicity. Side effects related to bevacizumab are not your garden-variety chemotherapy side effects, nor are they similar to toxicity from immunotherapy. Rather, they stand apart, unique amongst our sy...
101. Castration-Resistant Prostate Cancer Update 11.05.2024 33:38
As many philosophers have noted, life often travels in cycles. Almost two years and more than 100 episodes ago, on a virtual call far far away, two young oncologists started on a journey to bring the latest oncology evidence to anyone with ears and the will to listen. Now, for episode number 101, Josh and Michael return to where it all started: prostate cancer. Much has changed in the (nearly) two...
100. 100th Episode Bonanza 04.05.2024 28:19
For 100 episodes, Josh and Michael have brought to your ears the latest and greatest in oncology research and treatment. In this episode, we will take a trip down memory lane, speaking about our journey up to this point, our favourite guests and favourite trials, and give you a glimpse of what the future holds for Oncology for the Inquisitive Mind. If we're honest, we never expected to get this fa...
99. Early Mutation-Driver Positive NSCLC 27.04.2024 33:48
In this episode, Josh and Michael examine the rapidly developing world of early lung cancer treatment. An area that will hopefully only grow in importance, treatment for early NSCLC is becoming ever more sophisticated, with recent developments in neoadjuvant management and confirmation of the benefit of adjuvant driver-mutation inhibitior treatment. Today's articles cover two such topics: will osi...
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.